TP53 Codon 72 Polymorphism and Risk of Acute Leukemia |
Dunna, Nageswara Rao
(School of Chemical & Biotechnology, SASTRA University)
Vure, Sugunakar (Department of Genetics, Osmania University) Sailaja, K. (Department of Genetics, Osmania University) Surekha, D. (Department of Genetics, Osmania University) Raghunadharao, D. (Department of Medical Oncology, Nizams Institute of Medical Sciences) Rajappa, Senthil (Department of Medical Oncology, Nizams Institute of Medical Sciences) Vishnupriya, S. (Department of Genetics, Osmania University) |
1 | Teodoro J.G, Sara K, Evans, et al (2007). Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome: J Mol Med, 85, 1175-86. DOI |
2 | Thomas M, Kalita A, Labrecque S, et al (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol, 19, 1092-100. DOI |
3 | Wang YC, Lee HS, Chen Sk, et al (1999). Prognostic significance of p53 in growth control and neoplasia. Eur J Cancer, 35, 226-30. DOI |
4 | Weston A, Ling-Cawley HM, Caporaso NE, et al (1994). Determination of the allelic frequencies of an L-myc and a p53polymorphism in human lung cancer. Carcinogenesis, 15, 583-7. DOI |
5 | Hu G, Zhang W, Deisseroth AB (1992). P53 gene mutations myelogenous leukaemia. Br J Haematol, 81, 489-94. DOI |
6 | Ko LJ, Prives C (1996). p53: puzzle and paradigm. Genes Dev, 10, 1054-72. DOI |
7 | Lahari D, Nuremberg J (1991). A rapid non-enzymatic method for the preparation of HMW DNA from blood RFLP studies. Nucleic Acid Research, 19, 5444-?. DOI |
8 | Lane DP, Benchimol S (1990). p53: oncogene or anti-oncogene? Genes & Development, 4, 1-8. DOI |
9 | Martin MC, Jost CA, Brooks LA, et al (2000). A common polymorphism acts as an intragenic modifier of mutant p53 behavior. Nat Genet, 25, 47-54. DOI |
10 | Nigro JM, Baker SJ, Preisinger AC Jessup JM, et al (1989). Mutation in the p53 gene occur in diverse human tumour types. Nature, 342, 705-8. DOI |
11 | Nurbuyru, Hatice Tigli, Nejat Dalay (2003). p53 codon 72 polymorphism in breast cancer. Oncology Reports, 10, 711-4. |
12 | Olivier M, Eeles R, Hollstein M, et al. (2002) Hum Mutat, 19, 607-14. DOI |
13 | Preudhomme C, Fenaux P (1997). the clinical significance of mutation of the p53 tumor suppressor gene in haematological malignances. Br J Haematol, 98, 502. |
14 | Prives C (1998). Signaling to p53: Breaking the MDM2-p53 circuit. Cell, 95, 5-8. DOI |
15 | Siddique MM, Balram C, Fiszer-Maliszewska L, et al (2005). Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol Biomarkers Prev, 14, 2245-52. DOI |
16 | BenYehuda D, Krichevsky S, Caspi O, et al (1996). Microsatellite instability and p53 mutation in therapy-related leukemia suggest mutator photypes, Blood, 88, 3022-6. |
17 | Slingerland JM, Minden MD. Benchimol S (1991). Mutation of the p53 gene in human acute myelogenous Leukemia. Blood, 77, 1500-7. |
18 | Sugimoto K, Toyoshima H, et al (1992). Frequent mutation in the p53 gene in human myloid leukemia cell lines. Blood, 79, 2378-883. |
19 | Beckman G, Birgander Z, Sjalander A, et al (1994). Is p53 polymorphism maintained by natural selection? Hum Hered, 44, 266-70. DOI |
20 | Bergamaschi D, Samuels Y, Sullivan A, et al (2006). iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet, 38, 1133-41. DOI |
21 | Crook T, Ludwing RL, Marston N, et al (1996). Sensitivity of p53 lysine mutants to ubiqitin-directed degradation targeted by human papillomavirus. Virology, 217, 285-92. DOI |
22 | Donehower LA, Bardley A (1993). The tumor suppressor p53. Biochimica et Biophysica Act, 1155, 181-205. |
23 | Dumont Patrick, J. I-Ju Leu , Anthony C, et al (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genetics, 33, 357-65. DOI |
24 | Fenaux P, Preudhomme C, Quiquandon I, et al (1992). Mutation of the p53 gene in acute myeloid leukemia. Br J Haematol, 80, 178-83. DOI |
25 | Fenaux P, Preudhomme C, Quiquandon I, et al (1991). TP53 gene mutation in acute myeloid leukemia with 17p monosomy. Blood, 78, 1652-7. |
26 | Hollstein M, Shomer B, Greenblatt M, et al (1996) . Datebase of p53 gene somatic mutation in human tumors and cell lines. Nul. Acids Res, 24, 141-6. DOI |
27 | Gottlieb E, Moshe O (1998). P53 facilitates pRb cleavage in IL-3-deprived cells: novel pro-apoptotic activity of p53. EMBO J, 17, 3587-96. DOI |
28 | Greenblatt MS, Bennett Wp, Hollstein M, et al (1994). Mutation in the p53 tumor suppressor gene.clues to cancer etiology and molecular pathogenesis. Cancer Res, 54, 4855-78. |